Pandion Therapeutics Inc. Common Stock
PAND
PAND was delisted on the 31st of March, 2021.
0 hedge funds and large institutions have $0 invested in Pandion Therapeutics Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 75 closing their positions.
29.17% less ownership
Funds ownership: 29.17% → 0% (-29%)
100% less funds holding
Funds holding: 75 → 0 (-75)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $515M
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 75
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$64.5M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$63M |
| 3 |
Goldman Sachs
New York
|
-$47.8M |
| 4 |
VI
Versor Investments
New York
|
-$44.6M |
| 5 |
Magnetar Financial
Evanston,
Illinois
|
-$43.5M |
PAND Hedge Fund Activity: Q2 2021 in Review
0 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Pandion Therapeutics Inc. Common Stock (PAND) for Q2 2021, worth a combined $0 — down 100% from $515M a quarter earlier.
Sellers outnumbered buyers: 75 funds closed out of PAND and 0 opened new positions — a net loss of 75 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $64.5M sold.
- 0 institutional investors held Pandion Therapeutics Inc. Common Stock (PAND) as of Q2 2021, down from 75 in Q1 2021.
- Funds reported $0 of Pandion Therapeutics Inc. Common Stock stock for Q2 2021, down 100% quarter-over-quarter.
- 0 funds opened new Pandion Therapeutics Inc. Common Stock positions in Q2 2021 and 75 closed out, a net change of -75 holders.
- The largest Pandion Therapeutics Inc. Common Stock seller in Q2 2021 was BlackRock, an estimated $64.5M sold.
Based on aggregated 13F filings for Q2 2021.